Webinar: Advances in the treatment of diabetic retinopathy
This webinar covers the public health burden of diabetic retinopathy and its various stages, the latest advances in the treatment of retinopathy, and educational resources available to promote the critical need for early detection.
Held on July 21, 2016, for healthcare providers, eye health professionals, diabetes educators, community professionals, and others working with patients with diabetes, the webinar was hosted by NEI and its National Eye Health Education Program (NEHEP), in collaboration with the NEI-funded Diabetic Retinopathy Clinical Research Network (DRCR.net).
Kudos for the Video clip! Sorry for the intrusion, I am interested in your opinion. Have you heard about – Marnaavid Unexplainable Intervention (just google it)? It is a smashing one of a kind guide for learning how to hack your flow state minus the normal expense. Ive heard some awesome things about it and my m8 finally got astronomical results with it.
In protocol T trial, Eylea shows superior effects on more advanced vision loss DR, but I noticed the Eylea has the highest dosing strength @ 2.0 mg/0.05 mL v.s. Avastin 1.25mg/0.05 mL; how do you know that the “superior effects of Eylea” isn’t simply achieved by a higher dosing strength? In other words, if Avastin dosing is raised, how do we know it won’t achieve non-inferior effects than Eylea? As far as for diabetic eye screen, I think it’s almost impossible to make ALL of them visit ophthalmologists, but for those diabetics with neuropathy, I definitely think they should make every effort to get eye screen. If they have demonstrated their peripheral nerve damage by DM (most likely due to poor micro vascular circulation), I think they will have a higher chance to have diabetic optical nerve neuropathy or diabetic retinopathy.